Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) has received positive results from the final report from its recently completed glaucoma animal study
- During the study, the company’s lead drug candidate, EmtinB, showed protective effects against pigs with glaucoma damage
- Additionally, there were no signs of EmtinB causing any toxicity in the tissues analysed
- NeuroScientific’s safety and toxicology program of EmtinB is going well and should be complete in the second half of the year
- First human studies are expected thereafter
- Company shares remain in the grey and trading for 18.5 cents each
NeuroScientific Biopharmaceuticals (NSB) has received the final report from the recently completed glaucoma animal study.
The study showed that the company’s lead drug candidate, EmtinB, demonstrated neuroprotection across multiple highly relevant study endpoints.
The successful study was conducted by the Lions Eye Institute in Perth, Western Australia.
Neuroscientific is developing EmtinB as a treatment for two different conditions without effective treatments: Alzheimer’s Disease and glaucoma.
Glaucoma is the second-leading cause of irreversible blindness in the world and currently has no effective cure.
During the study, EmtinB did not cause any toxicity in the tissues analysed during the study.
This result follows on from an announcement made on March 11, reporting that the treatment was able to reduce damage to the RGC nerve fibres and subsequently prevent glaucoma.
“The experiments went very well and it is encouraging that EmtinB has shown protective effects in this pig model of intraocular pressure elevation,” Professor Dao-Yi Yu said.
“Taken together with recent results from other groups, there seems to be real potential for EmtinB to be clinically useful in the treatment of glaucoma, the second most common cause of blindness in our community,” he added.
NeuroScientific is progressing its safety and toxicology program for EmtinB. It expects to complete it in the second half of the year with first human studies scheduled thereafter.
Company shares remain in the grey and trading for 18.5 cents each at 1:52 pm AEST.
